Complement Therapeutics Enrols First Patient in Non- interventional i-GAIN Study of People Diagnosed with Geographic Atrophy
London England – 09 February 2023 – Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced enrolment of the first patient in a natural history study of people who have been diagnosed with geographic atrophy (GA), secondary to age-related macular degeneration (AMD); also called late dry AMD, GA is a disease which causes irreversible blindness and currently has no approved treatments.
The i-GAIN (investigating Geographic Atrophy Insights) study is a one-year natural history study in patients who have a confirmed diagnosis of GA in one or both eyes. The study is designed to evaluate the relationship between genetics, blood biomarkers and phenotypic changes in the eye of people with GA. Data from the i-GAIN study will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, particularly enabling the identification and stratification of patients with complement-driven AMD for future interventional studies.
Dr Marta Ugarte, consultant ophthalmologist and principal investigator of the i- GAIN study said “Today’s announcement is an important milestone in enabling researchers to gain a better understanding of this disease. We look forward to generating and analysing data from the i-GAIN study, which will provide insights into how the disease progresses.”
“A deeper understanding of the natural history of GA will provide important insights supporting the development of innovative medicines which can prevent vision loss in these patients,” said Dr Rafiq Hasan, Chief Executive Officer at Complement Therapeutics.
About the i-GAIN Study
i-GAIN is a multicentre, prospective natural history of people over 18 who have an established clinical diagnosis of GA. No investigational medications or treatments will be provided, as it is a non-interventional study. The study is expected to enrol approximately 250 patients across 12 sites in the United Kingdom. Patients will undergo assessments at baseline, 6 months and 12 months. For more information about enrolling in the study, please email iGAIN@complementtx.com.
About Complement Therapeutics Ltd:
Complement Therapeutics (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
For more information please visit: https://complementtx.com/
Dr Rafiq Hasan, CEO
Complement Therapeutics Ltd